Omnicell, Inc. (OMCL) Receives Average Recommendation of “Buy” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus rating of “Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $70.88.

A number of equities research analysts recently weighed in on OMCL shares. BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 9th. MED boosted their price target on shares of Omnicell from $59.00 to $71.00 and gave the company an “in-line” rating in a research report on Monday, October 22nd. Cantor Fitzgerald boosted their price target on shares of Omnicell from $63.00 to $70.00 and gave the company an “overweight” rating in a research report on Friday, October 26th. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. Finally, Oppenheimer upped their target price on shares of Omnicell from $71.00 to $73.00 and gave the company an “outperform” rating in a report on Friday, October 26th.

OMCL traded down $0.69 on Monday, reaching $71.56. The company had a trading volume of 2,099 shares, compared to its average volume of 369,866. Omnicell has a 1 year low of $39.75 and a 1 year high of $74.16. The stock has a market cap of $2.86 billion, a PE ratio of 398.11, a price-to-earnings-growth ratio of 4.32 and a beta of 0.98. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32.

In other news, Director James T. Judson sold 2,443 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $70.67, for a total value of $172,646.81. Following the completion of the sale, the director now directly owns 24,952 shares of the company’s stock, valued at $1,763,357.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James T. Judson sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $68.90, for a total transaction of $344,500.00. Following the completion of the sale, the director now directly owns 34,952 shares of the company’s stock, valued at $2,408,192.80. The disclosure for this sale can be found here. Insiders sold 24,267 shares of company stock valued at $1,653,616 over the last ninety days. Corporate insiders own 3.71% of the company’s stock.

Several large investors have recently made changes to their positions in OMCL. SFE Investment Counsel raised its holdings in Omnicell by 34.0% during the second quarter. SFE Investment Counsel now owns 9,743 shares of the company’s stock worth $511,000 after purchasing an additional 2,471 shares in the last quarter. West Coast Financial LLC raised its holdings in Omnicell by 3.7% during the third quarter. West Coast Financial LLC now owns 115,580 shares of the company’s stock worth $8,310,000 after purchasing an additional 4,126 shares in the last quarter. Kopp Investment Advisors LLC raised its holdings in Omnicell by 2.6% during the second quarter. Kopp Investment Advisors LLC now owns 69,077 shares of the company’s stock worth $3,623,000 after purchasing an additional 1,757 shares in the last quarter. Everence Capital Management Inc. purchased a new position in Omnicell during the third quarter worth about $204,000. Finally, Janus Henderson Group PLC raised its holdings in Omnicell by 52.1% during the second quarter. Janus Henderson Group PLC now owns 1,513,979 shares of the company’s stock worth $79,408,000 after purchasing an additional 518,824 shares in the last quarter.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Read More: Index Funds

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply